Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
VIVESTO AB |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 0.1734 SEK | -4.20% | -11.44% | -60.05% | |
| Nov. 23 | Vivesto AB Announces Composition of Nomination Committee | CI |
| Nov. 23 | Vivesto Abandons Apealea Partnership with Elevar Therapeutics | MT |
| Sales 2022 | 3.04M 290K | Sales 2023 * | - | Capitalization | 234M 22.27M |
|---|---|---|---|---|---|
| Net income 2022 | -357M -34.05M | Net income 2023 * | - | EV / Sales 2022 | 32,6x |
| Net cash position 2022 | 134M 12.81M | Net cash position 2023 * | - 0 | EV / Sales 2023 * | - |
| P/E ratio 2022 | -0,60x | P/E ratio 2023 * | Employees | 14 | |
| Yield 2022 | - | Yield 2023 * |
-
| Free-Float | 61.13% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -4.20% | ||
| 1 week | -11.44% | ||
| Current month | -9.59% | ||
| 1 month | -10.06% | ||
| 3 months | -23.27% | ||
| 6 months | -41.02% | ||
| Current year | -60.05% |
1 week
0.16
0.20
1 month
0.160.22
Current year
0.160.47
1 year
0.160.55
3 years
0.164.59
5 years
0.1611.76
10 years
0.1631.30
| Managers | Title | Age | Since |
|---|---|---|---|
Erik Kinnman
CEO | Chief Executive Officer | 65 | Jan. 22 |
Robert Maiorana
DFI | Director of Finance/CFO | 63 | 2020 |
Kai Wilkinson
CTO | Chief Tech/Sci/R&D Officer | 42 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 43 | 2019 | |
Hege Hellstrom
BRD | Director/Board Member | 58 | 2019 |
Pål Ryfors
BRD | Director/Board Member | 40 | 2022 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-05 | 0.1734 | -4.20% | 1,861,322 |
| 23-12-04 | 0.181 | -3.62% | 149,872 |
| 23-12-01 | 0.1878 | -2.09% | 1,907,797 |
| 23-11-30 | 0.1918 | +0.52% | 757,296 |
| 23-11-29 | 0.1908 | -2.45% | 487,239 |
Delayed Quote Nasdaq Stockholm, December 05, 2023 at 11:23 am EST
More quotes
Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.
Sector
Pharmaceuticals
Calendar
2024-02-21
- Q4 2023 Earnings Release
Trading Rating :
Investor Rating :
ESG Refinitiv :
C-
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -60.05% | 9 M $ | |
| +60.77% | 527 B $ | |
| +46.50% | 448 B $ | |
| -10.25% | 382 B $ | |
| -4.25% | 266 B $ | |
| -10.54% | 255 B $ | |
| -13.61% | 227 B $ | |
| +1.76% | 203 B $ | |
| -9.57% | 201 B $ | |
| -43.23% | 165 B $ |
